Surgery Partners' Growth Prospects Bolster Buy Rating
Surgery Partners (SGRY) Outperforms With Strong Q1 and Strategic Focus: A Buy Rating Maintained
Surgery Partners Analyst Ratings
Citigroup Maintains Buy on Surgery Partners, Lowers Price Target to $38
Surgery Partners: Strong Fundamentals and Market Trends Justify Buy Rating Amidst Favorable Growth Projections
Analysts Offer Insights on Healthcare Companies: Surgery Partners (SGRY), Repare Therapeutics (RPTX) and Penumbra (PEN)
Surgery Partners (SGRY) Gets a Buy From RBC Capital
Barclays Sticks to Its Hold Rating for Surgery Partners (SGRY)
Analysts' Top Healthcare Picks: IDEAYA Biosciences (IDYA), Surgery Partners (SGRY)
Surgery Partners Analyst Ratings
Surgery Partners Analyst Ratings
Surgery Partners: A Buy Rating Amidst Underperformance and Growth Potential
Surgery Partners Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Surgery Partners, Maintains $43 Price Target
Surgery Partners Analyst Ratings
RBC Capital Sticks to Its Buy Rating for Surgery Partners (SGRY)
Surgery Partners: A Buy Rating With Upside Potential on Strong FCF and Growth Prospects
Surgery Partners Analyst Ratings
Cantor Fitzgerald Sticks to Its Buy Rating for Surgery Partners (SGRY)
Surgery Partners' Expansion and Positive Earnings Outlook Prompt 'Buy' Rating
No Data